Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

Open access
Savina, Marion, Le Cesne, Axel, Blay, Jean-Yves, Ray-Coquard, Isabelle, Mir, Olivier, Toulmonde, Maud, Cousin, Sophie, Terrier, Philippe, Ranchere-Vince, Dominique, Meeus, Pierre, Stoeckle, Eberhard, Honoré, Charles, Sargos, Paul, Sunyach, Marie-Pierre, Le Péchoux, Cécile, Giraud, Antoine, Bellera, Carine, Le Loarer, François, Italiano, Antoine · 2017 · BMC Medicine

Abstract

BACKGROUND: Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals. METHODS: The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group were analyzed. RESULTS: The median number of systemic treatments was 3 (range, 1-6); 27% of the patients did not receive any systemic treatment and 1054 (49%) patients underwent locoregional treatment of the metastasis. Half of the patients who underwent chemotherapy (n = 810) received an off-label drug. Leiomyosarcoma was associated with a significantly better outcome than the other histological subtypes. With the exception of leiomyosarcomas, the benefit of a greater than third-line regimen was very limited, with a median time to next treatment (TNT) and overall survival (OS) ranging between 2.3 and 3.7 months and 5.4 and 8.5 months, respectively. The TNT was highly correlated with OS. Female sex, leiomyosarcoma histology, locoregional treatment of metastases, inclusion in a clinical trial, and treatment with first-line polychemotherapy were significantly associated with improved OS in the multivariate analysis. CONCLUSIONS: The combination of doxorubicin with a second drug, such as ifosfamide, represents a valid option, particularly when tumor shrinkage is expected to provide clinical benefits. After failure of the second-line therapy, best supportive care should be considered, particularly in patients with non-leiomyosarcoma histology who are not eligible to participate in a clinical trial. Locoregional treatment of metastasis should always be included in the therapeutic strategy when feasible. TNT may represent a useful surrogate endpoint for OS in clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-017-0831-7

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 208

Metadata

Authors
Savina, M., Le Cesne, A., Blay, J.-Y., Ray-Coquard, I., Mir, O., Toulmonde, M., Cousin, S., Terrier, P., Ranchere-Vince, D., Meeus, P., Stoeckle, E., Honoré, C., Sargos, P., Sunyach, M.-P., Le Péchoux, C., Giraud, A., Bellera, C., Le Loarer, F., & Italiano, A.
Venue
BMC Medicine
Published
2017-04-10
Volume
15
Issue
1
Pages
78-78
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2605016673
Cited by
208
References
1
FWCI
13.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. https://app.cochat.ai/papers/10.1186/s12916-017-0831-7
The paper
Savina, M., Le Cesne, A., Blay, J.-Y., Ray-Coquard, I., Mir, O., Toulmonde, M., Cousin, S., Terrier, P., Ranchere-Vince, D., Meeus, P., Stoeckle, E., Honoré, C., Sargos, P., Sunyach, M.-P., Le Péchoux, C., Giraud, A., Bellera, C., Le Loarer, F., & Italiano, A. (2017). Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Medicine. https://doi.org/10.1186/s12916-017-0831-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.